Discussions marquées : MSF

Vacancy: Vaccination operations focal point, MSF-USA

Julien Potet Publié dans :
http://www.doctorswithoutborders.org/work-us/work-office/office-employment The NY office of MSF-USA is seeking a full time operational liaison to advance progress on vaccination in target countries but also across the entire portfolio including vaccination in emergency situations. The position will liaise and work closely with the MSF OCP desks and med department and coordinate with the movement's vaccination platforms. the position will be a key facilitator for advancing MSF OCP immunization objectives and the communications and advocacy linked to those operations. Position Responsibilities To act as the focal point linking field operations, medical referents, access campaign vaccine responsible and communications dept in translating field experience into communication, campaign and advocacy messaging.  Link the operational advances (Med-Ops) to the Access Campaigns advocacy and communications work on products, prices and policies providing field-based context examples for reports, PR’s, op-eds, social media campaigns conferences/workshops . Liaise with OCP communications/MSF USA/CAME to support communications messaging and strategy around vaccination operations linked to CAME advocacy agenda. Liaise closely with the desk for Chad and South Sudan and the country vaccination focal points (under recruitment) to advance MSFF’s priority country work; also with all desks including emergency desk on the introduction of new vaccines in emergency contexts. To document successes and constraints and integrate these elements into the advocacy and communications campaign. According to country level obstacles identified by the country vaccination focal point (in 4 target countries) or by the desks in other countries (including immunization in emergency situations) this position will provide advocacy support in collaboration with Access campaign and Medical advisors to challenge/resolve these obstacles. Internal communications: Provide regular feedback to medical and operations direction, NY office and operations depts, evaluation of progress, adaptation of strategies etc Deliver presentations on country experience, provide interviews, etc., as requested. Accompany Vaccine medical referent visits to fields (especially priority fields) if feasible, to understand areas for improving routine immunization, innovative vaccination activities, use of new vaccines, etc. Participate in any relevant country level workshops to support plan development, gather operational advocacy/communications material. Develop a yearly budget for expenses directly related to the position. Qualifications A desirable candidate encompasses the following qualifications, competencies, and experience: Project management “experience; analysis of problematic, analysis, strategic planning and implementation. Experience working with MSF in the field at a project management level Ability to work and facilitate a wide group of individuals with diverse expertise Medical/Non-med/communications or advocacy background; understanding of public health an advantage Experience working with vaccination programs a plus Excellent writing and communications skills Bilingual in French/English Availability to travel up to 40% Status: CDD 1 year Permanent contract, full time basis based in NY able to spend 25% in Paris and short visits to field or within Europe. The nature of your employment contract and salary will be determined by your administrative situation. Starting Date: asap Please send your application letter (letter of motivation and resume) by email at: emploi @ paris.msf.org by September, 22nd 2014 Indicate the following reference in the mail subject line: VAC/FP-0814

MSF INTERNATIONAL - Access Campaign - Vaccines and Special Project Pharmacist - VSPP

Deleted User Publié dans :
Reporting to the Access Campaign Pharmaceutical Coordinator, the Vaccines and Special Project Pharmacist (VSPP) will support the pharmaceutical activities of the Access Campaign on key vaccines and on special projects aimed at investigating access barriers to targeted product categories. The main focus of the VSPP's work will be research, analysis and data collection relating to key vaccines. The VSPP plays a crucial role in solving access problems and in maintaining contacts with pharmaceutical companies and identifying new manufacturers for key products. The VSPP will especially look at regulatory barriers for market entry for vaccines and products in line with the special projects. Starting Date: October 2014, Contract: 2 year contract - 100%, Location: One of MSF's 5 operational centres, preferably Paris or Geneva, Deadline for the applications: 31 August 2014, Please submit all applications only by email to: IO-recruitment.gva@msf.org stating “VSPP” in the title. Please submit your CV and cover letter in ONE file and name the file with your last name. Only short-listed candidates will be contacted-

World Immunization Week: MSF calling for heat-stable vaccines to help reach the one in five children

This note has been cross-posted from the GAVI CSO forum with many thanks! Dear colleagues, This week on occasion of the World Immunization Week, Médecins Sans Frontières/Doctors Without Borders (MSF) has released a call for greater attention to the need for heat-stable vaccines to facilitate access to life saving vaccinations to the one in five children currently left out of global immunization efforts. You can find more information on the call for heat-stable vaccines below, including information that explains the challenges that medical organisations like MSF and governments face in reaching all children in need. The requirement for vaccines to be kept constantly cold is proving a barrier in improving immunization coverage rates. We are asking pharmaceutical companies, governments and philanthropic R&D funders to urgently take steps to increase the thermostability of existing vaccines, and develop new vaccines that are easier to use - with greater tolerance for heat - to reduce the logistical hurdles imposed by the ‘cold chain.’ Currently, the requirement to keep vaccines between 2°C and 8°C is a major obstacle for MSF and other partners delivering vaccination to the children who are disproportionately affected by vaccine-preventable diseases. Cold chain challenges could be eased if pharmaceutical companies generated and released more information on the true heat sensitivity of their vaccines. For example, this week, we are releasing the results of a new MSF study that shows a tetanus vaccine remains effective for up to a month when used outside of a strict cold chain For more information, please read our new Issue Brief: Vaccinating Children beyond the 'Cold Chain', available at the link below and also available in French, attached: http://www.msfaccess.org/content/issue-brief-vaccinating-children-beyond-cold-chain Finally, we are also launching a new website where you can find information about MSF's vaccination work: http://www.msfaccess.org/bestshot Do not hesitate to contact us if you require any further information or have any questions. Thank you and kind regards, Kate Elder Vaccines Policy Advisor Médecins Sans Frontières | Access Campaign 333 7th Avenue, 2nd floor New York, NY 10001 Tel: +1 212 763 5737 Cell: +1 917 213 5365 kate.elder@msf.org http://www.msfaccess.org/about-us/media-room/press-releases/heat-stable-vaccines-urgently-needed-reach-one-five-children#overlay-context=

Special session on vaccines at MSF conference

Moderator Publié dans :
Thank you Dr Robert Steinglass for sharing these presentations and films with the forum. Doctors Without Borders/Médecins Sans Frontières (MSF), the Drugs for Neglected Diseases initiative (DNDi) and Mount Sinai School of Medicine's Global Health Program conducted a conference titled "Lives in the Balance: Delivering Medical Innovations to Neglected Patients and Populations" conference from December 13-14, 2012. There were more than 500 registered participants, including key actors in global health and R&D personnel from more than 20 countries, who took stock of the efforts to stimulate needs-driven R&D and participated in lively discussions about how to confront the challenges we face today. The conference website has been updated to include videos from each panel, the PowerPoint presentations delivered over the two days, as well as the Fatal Neglect films that people can use to highlight the conference themes at a variety of fora: http://www.doctorswithoutborders.org/events/symposiums/2012-lives-in-the-balance/ The focused vaccine session at the conference was moderated by Robert Steinglass, Immunization Senior Advisor, JSI The short presentations setting the stage were by: Samba Ousmane Sow, MD, Center for Vaccine Development-Mali (CVD-Mali) - A case study on using TT-Uniject in Mali Rebecca Grais, PhD , Epicentre - Optimizing vaccinations in emergencies - what products are needed The panel discussion members were: Fred Were, MD, Chairman of the Kenya Pediatric Association F. Marc La Force, MD, Serum Institute of India Nina Schwalbe, Managing Director, Policy & Performance, GAVI Alliance Paul Herrling, PhD, Professor, Chair Novartis Institute for Tropical Diseases, Novartis Pharma AG

GAVI's push for more funds questioned by MSF

Dear Moderator, I wish to underline that GAVI's push for more funds for vaccines has been questioned by the MSF. I think GAVI needs to respond to MSF and clarify their stand so that everyone knows why is something being done and at what cost. Also we wish to know what is GAVI doing for transfer of technology to third world countries to bring prices of vaccines to lowest possible level and cut profits of big pharma e.g. in case of intradermal use of many vaccines, not only costs can be upto five times less but we would spare the vaccines as well to immunize more children. MSF says.... Emerging country suppliers like India’s Serum Institute have said they could sell similar pneumococcal vaccine products for US$2 (£1.25) a dose – a 40 percent reduction on the GSK and Pfizer price The executive director of Serum Institute, Dr Suresh Jadhav, said recently that if his company had not faced patent restrictions, the vaccine could have been available by next year – now it is not expected until 2015. Technology transfer and product development grants to low-cost suppliers are being supported by the Bill and Melinda Gates Foundation, but these sums are dwarfed by the Advance Market Commitment subsidy to Big Pharma....for details the link is as follows; http://www.msfaccess.org/main/vaccines/gavi-money-welcome-but-could-it-be-more-wisely-spent/ http://www.msfaccess.org/main/vaccines/gavi-money-welcome-but-could-it-be-more-wisely-spent/ Thanks and regards, Dr. Omesh K Bharti, India
  • Page :
  • 1